About | Apheris

WHAT WE DO

From federated models to drug discovery decisions

We turn the industry’s proprietary data into models no public dataset can match, then deliver them into your own environment, to run, fine-tune, benchmark, and sharpen with every DMTA cycle.

Federated networks

Members contribute proprietary data to a shared network. Training runs inside each member’s own environment; only model weights are ever aggregated.

Neutral by design

Apheris operates the networks and runs no drug programs of its own. Pharma build with us because we don’t compete with them.

Adopted through Foundry

The advantage reaches your programs through Foundry, the platform your teams run in-house to put these models to work across the DMTA cycle.

LEADERSHIP

Meet our founders

Robin Röhm

Co-Founder & CEO

Robin studied medicine, philosophy and mathematics and was trained in global banking at UBS. In a previous start-up, he lost multiple customers as data could not be centralized due to regulatory constraints. He drives the vision, strategy, and culture of Apheris.
‍

Michael Höh

Co-Founder & CTO

Michael has a PhD in physics and computer science and was trained at BCG, where he built digital solutions and AI applications for industrial clients. As CTO he leads platform architecture and design, the engineering target picture, technical customer commitments, and contractual scoping.
‍

SCIENTIFIC ADVISORY BOARD

Guided by leaders in drug discovery and computational science

Our Scientific Advisory Board brings together leaders from academia, biotech, and pharma who have shaped drug discovery and computational science. With decades of combined experience in AI, molecular modeling, and building world-class research organizations, they guide our scientific strategy.

Dr. Woody Sherman

Founder & Chief Innovation Officer, PsiThera

Integrates computational methods with wet-lab experiments to design therapeutics for targets long considered undruggable. Original architect of the QUAISAR platform, 100+ peer-reviewed publications; formerly Silicon Therapeutics, Roivant, and Schrödinger. PhD in Physical Chemistry, MIT.

Dr. Richard Bickerton

Co-Founder, Exscientia

Co-founded Exscientia and helped build its AI-first discovery platform, later acquired by Recursion. Background spans cheminformatics, large-scale ML systems, and data science, with experience across technology, biotech, and company building.

Dr. Andreas Bender

Professor of Machine Learning in Medicine, Khalifa University

Former Professor of Molecular Informatics at Cambridge; senior roles at AstraZeneca and Nuvisan in data science and AI. Co-founder of Healx and PharmEnable and former CITO at Pangea Bio, with programs in clinical development.

Dr. Mohammed AlQuraishi

Assistant Professor, Columbia University

His lab in the Department of Systems Biology develops AI models for protein structure, function, and protein–ligand interaction. Built OpenFold, the leading open-source structure prediction model, and is spearheading OpenFold3.

Dr. Pamela Carroll

Former COO, Isomorphic Labs

Executive leadership roles across pharma and biotech, including business development at Roivant and J&J, and scientific leadership in oncology at Roche and Merck. Recognized for integrating emerging platforms to accelerate discovery of novel medicines.

Dr. Darren Green

Former Head of Cheminformatics, GSK; Hon. Professor, UCL

More than three decades applying advanced computational methods to drug discovery across therapeutic areas. A pioneer in applying federated learning to drug discovery ML, including as part of the MELLODDY project.

Dr. Joseph Lehár

Entrepreneur; former SVP R&D Strategy, Owkin

Led computational biology and bioinformatics groups across major pharma and biotech, including senior roles at Owkin, Merck, J&J, and Google. Work spans collaborative R&D models, translational science, and data-driven discovery.